SCHEMBL19950469

SCHEMBL19950469

CC(C)NC(=O)OCc1cc(F)c(B2OC(C)(C)C(C)(C)O2)c(F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 9/20 0.36
TSHR P16473 8/20 0.36
ALDH1A1 P00352 4/20 0.36
TOP2A P11388 2/20 0.35
TOP2B Q02880 2/20 0.35
ATM Q13315 1/20 0.35
CYP2C9 P11712 6/20 0.33
CYP2C19 P33261 5/20 0.33
CYP1A2 P05177 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
LMNA P02545 3/20 0.33
CYP2D6 P10635 2/20 0.33
CTSK P43235 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
HDAC1 Q13547 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
HDAC5 Q9UQL6 1/20 0.32
MEN1 O00255 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19948906 0.80 TOP2A (0.32) TOP2ATOP2BSMN1; SMN2MEN1KMT2A
SCHEMBL19950212 0.79 TOP2A (0.30) TOP2ATOP2B
SCHEMBL15254859 0.79 LIPG (0.46) CYP3A4TSHRALDH1A1TOP2ATOP2B
SCHEMBL12078517 0.76 LPL (0.32)
SCHEMBL15872764 0.74 LPL (0.34)
SCHEMBL23417787 0.73 LMNA (0.43) CYP3A4TSHRALDH1A1TOP2ATOP2B
SCHEMBL23417785 0.73 TOP2A (0.41) CYP3A4TSHRALDH1A1TOP2ATOP2B
SCHEMBL26422908 0.73 TOP2A (0.41) CYP3A4TSHRALDH1A1TOP2ATOP2B
SCHEMBL29344082 0.72 TOP2A (0.38) TOP2ATOP2BATMSMN1; SMN2LMNA
SCHEMBL15572907 0.72 LPL (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 US disclosed
EP-4119558-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF Incyte Corporation (US) 2023-01-18 EP disclosed
EP-3510032-B1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORP (US) 2022-07-06 EP disclosed
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-09 US disclosed
US-10934288-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2021-03-02 US disclosed
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-19 US disclosed
US-10435405-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-10-08 US disclosed
US-10266530-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-04-23 US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 US disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 CYP3A4 1456/4885TSHR 4733/4885ALDH1A1 2205/4885
US-11795166-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 CYP3A4 1456/4885TSHR 4733/4885ALDH1A1 2205/4885
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 CYP3A4 1456/4885TSHR 4733/4885ALDH1A1 2205/4885
US-10934288-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 CYP3A4 1456/4885TSHR 4733/4885ALDH1A1 2205/4885
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 CYP3A4 1456/4885TSHR 4733/4885ALDH1A1 2205/4885
US-10435405-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 CYP3A4 1456/4885TSHR 4733/4885ALDH1A1 2205/4885
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 CYP3A4 1456/4885TSHR 4733/4885ALDH1A1 2205/4885
US-10266530-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 CYP3A4 1456/4885TSHR 4733/4885ALDH1A1 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.